🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07110051
Recruiting Not applicable

Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient

NCT07110051 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-15
Last updated
2025-08-11

Condition(s) studied

TramadolNalbuphineAbdominal SurgeriesPediatric Cancer

Investigational drug(s) / intervention(s)

Nalbuphine →Tramadol →

Nalbuphine: this group will a single dose of nalbuphine (0.2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)

Tramadol: this group will receive a single dose of tramadol (2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).

Study summary

In current study the investigators aim to compare between nalbuphine versus tramadol for post-operative pain control in abdominal surgeries in pediatric.

Eligibility

Sex
ALL
Min age
3 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Participants will be children aged 3-12 years * American society of anesthesia (ASA) classification I-III. * scheduled for elective Abdominal surgery under general anesthesia Exclusion Criteria: * child guardian refusal. * Allergy from Tramal or nalbuphine * Patient with previous chronic pain on opioids

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National cancer institute Cairo Egypt Recruiting

More National Cancer Institute, Egypt trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07110051 on ClinicalTrials.gov ↗ ← All trials in Egypt